Back to homepage

Haematology and Oncology

Leptomeningeal carcinomatosis and breast cancer: a systematic review of current evidence on diagnosis, treatment and prognosis

Authors: Ludovica Mollica, Claudia Leli, Silvia Puglisi, Silvia Sardi, Federico Sottotetti

This article is a systematic review of the evidence published over the last two decades, focusing on recent advances in the diagnostic
and therapeutic options of leptomeningeal carcinomatosis.

More▸

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma

Authors: Omar Castaneda-Puglianini, Julio C Chavez

This article is a narrative review of the most current data on bispecific antibodies in B cell non-Hodgkin’s lymphoma and multiple myeloma.

More▸

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma

Authors: Francesco Serra, Carlotta Faverio, Angioletta Lasagna, Stefania Barruscotti, Tommaso Dominioni, Marco Benazzo, Paolo Pedrazzoli, Silvia Chiellino

The aim of this review is to investigate the role of treatment beyond progression and locoregional approaches in BRAF-mutated metastatic melanoma and provide oncologists dealing with this malignancy a useful road map on when and why to choose this strategy.

More▸

Therapeutics for paediatric oncological emergencies

Authors: Karen Ka Yan Leung, Kam Lun Hon, Wun Fung Hui, Alexander KC Leung, Chi Kong Li

Keywords: acute respiratory distress syndrome (ARDS), Cancer, critical care, disseminated intravascular coagulation, hyperleukocytosis, oncologic emergency, paediatrics, posterior reversible encephalopathy syndrome (PRES), sepsis, superior mediastinal syndrome, therapeutics, treatment, tumour lysis syndrome. Citation: Leung KKY, Hon KL, Hui WF, Leung AKC, Li

More▸

Volume matters and intensification is needed: emerging trends in the management of advanced prostate cancer

Authors: Iris Y Sheng, Pedro Barata, Raafat Alameddine, Jorge A Garcia

The aim of this narrative review is to discuss the importance of defining advanced disease by volume, the necessity for treatment intensification, and the current and future landscape of metastatic hormonesensitive prostate cancer management.

More▸